EUCTR2011-002461-37-HU进行中（未招募）不适用
A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES - Optimising Combination Therapy On Partial Onset Seizures (OCToPOS)
CB BIOSCIENCES Inc0 个研究点目标入组 100 人开始时间: 2012年9月25日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subject is male or female, at least 18 years of age.
- •2. Subject has a diagnosis of epilepsy with partial-onset seizures according to the International Classification of Epileptic Seizures (1981).
- •3. Subject is taking LEV in combination with 1 sodium channel blocking antiepileptic drug (defined as carbamazepine, lamotrigine, oxcarbazepine, phenytoin, or eslicarbazepine) as adjunctive treatment for epilepsy.
- •4. The minimum required seizure frequency during the 8-week Retrospective Seizure Baseline is on average =2 partial-onset seizures per 28 days with at least 1 seizure per 4 week period within the 8-week Retrospective Seizure Baseline. Additionally, subjects must experience at least 1 seizure during the 4-week Prospective Seizure Baseline.
- •5. Subject has been maintained on a stable dose of LEV and a sodium channel blocking antiepileptic drug for at least 4 weeks prior to the Screening Visit (Visit 1) and during the 4-week Prospective Seizure Baseline.
- •6. The minimum required seizure frequency during the 8-week Retrospective Seizure Baseline is on average =2 partial-onset seizures (IA, IB, or IC) per 28 days (based on investigator assessment of subject report) with at least 1 seizure per 4 week period within the 8-week Retrospective Seizure Baseline.
- •7. Subject has been maintained on a stable dose of LEV and a SCB-AED for at least 4 weeks prior to the Screening Visit (Visit 1) and during the 4-week Prospective Seizure Baseline, with or without additional concurrent stable vagal nerve stimulation (VNS). The VNS must have been in place for at least 6 months prior to the Screening Visit (Visit 1) with constant settings for at least 4-weeks prior to the Screening Visit (Visit 1) and throughout the duration of the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 98
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2
排除标准
- •1. Previous use of lacosamide.
- •2. History of alcohol or drug abuse.
- •3. History of seizure disorder characterized primarily by isolated auras.
- •4. History of primary generalized seizures.
- •5. History of status epilepticus within the 12-months.
- •6. History of clustering seizures.
- •7. Nonepileptic events, including pseudoseizures that could be confused with seizures
- •8. History of any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize the subject’s health or would compromise the subject’s ability to participate in this study.
- •9. Lifetime history of suicide attempt,or suicidal ideation in the past 6 months.
- •10. Hypersensitivity to any component of LCM.
- •11. History of acute or sub-acute progressive central nervous system disease.
- •12. History of severe anaphylactic reaction or serious blood dyscrasias.
- •13. Impaired renal function (ie, creatinine clearance [CLcr] is lower than 30mL/min) at Visit 1.
- •14. History of sick sinus syndrome without a pacemaker, or atrioventricular (AV) block, or subject has any other clinically significant ECG abnormalities.
- •15. History sodium channelopathy, such as Brugada syndrome.
- •16. History of myocardial infarction in the last 3 months.
研究者
相似试验
进行中（未招募）
不适用
AN EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHENADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002461-37-DECB BIOSCIENCES Inc100
进行中（未招募）
不适用
AN EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHENADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURESEUCTR2011-002461-37-SECB BIOSCIENCES Inc100
撤回
3 期
A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURESpartial onset seizures10039911epilepsyNL-OMON37460CB Biosciences Inc25
进行中（未招募）
不适用
AN EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHENADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002461-37-ATCB BIOSCIENCES Inc300
进行中（未招募）
不适用
AN EXPLORATIVE STUDY TO EVALUATE THE TOLERABILITY AND EFFICACY OF LACOSAMIDE WHENADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURESEpilepsy with partial onset seizuresMedDRA version: 14.1Level: PTClassification code 10015037Term: EpilepsySystem Organ Class: 10029205 - Nervous system disordersEUCTR2011-002461-37-NLCB BIOSCIENCES Inc300